No Data
Shanghai Hile Bio-Technology (603718.SH): Subsidiary re-evaluated as a high-tech enterprise.
On March 6, Gelonghui reported that Shanghai Hile Bio-Technology (603718.SH) announced that its wholly-owned subsidiary, Shanghai Jiemei Biotechnology Co., Ltd. (hereinafter referred to as "Jiemei Biotechnology"), recently received the "High-tech Enterprise Certificate" jointly issued by the Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau, and the State Taxation Administration Shanghai Taxation Bureau. Date of issuance: December 4, 2024, validity period: three years. The recognition of Jiemei Biotechnology as a high-tech enterprise this time is a re-evaluation after the original certificate expired.
Shanghai Hile Bio-Technology (603718.SH): Director and General Manager Han Benyi intends to reduce his Shareholding by no more than 0.75 million shares.
Gelonghui, February 19丨Shanghai Hile Bio-Technology (603718.SH) announced that Mr. Han Benyi, Director and General Manager, intends to reduce his shareholding in the company through a centralized bidding trading method due to personal funding needs. The number of shares to be reduced will not exceed 750,000 shares, which is no more than 0.1140% of the company's total share capital, and no more than 25% of his holdings in the company. The aforementioned reduction plan will be conducted within three months after the fifteenth trading day from the disclosure date of this announcement, and the reduction price will be determined based on the market price at the time of implementation.
Health Check: How Prudently Does Shanghai Hile Bio-Technology (SHSE:603718) Use Debt?
Hailey Biotech: Hailey Biotech 2024 Annual Results Advance Announcement
Hailey Biotech 2024 Annual Results Advance Announcement
Shanghai Hile Bio-Technology (603718.SH): Expected net income in 2024 to increase by 154.49% to 186.3% year-on-year.
On January 23, Gelonghui reported that Shanghai Hile Bio-Technology (603718.SH) announced that, 1. According to preliminary calculations by the finance department, the net income attributable to the shareholders of the listed company for the year 2024 is expected to be between 160 million yuan and 180 million yuan, an increase of 97.129797 million yuan to 117.129797 million yuan compared to the same period last year, representing a year-on-year growth of 154.49% to 186.30%. 2. The net income attributable to the shareholders of the listed company, after deducting non-recurring gains and losses, is expected to be between 8.2 million yuan and 12 million yuan, a decrease of 3.621974 million yuan compared to the same period last year.
More Unpleasant Surprises Could Be In Store For Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Shares After Tumbling 31%
